REVEL PHARMACEUTICALS INC. — Department of Health and Human Services SBIR Phase I: 270
REVEL PHARMACEUTICALS INC. — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $272,137
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 270
- Solicitation
- PA22-176
- NAICS
- —
- Place of performance
- CA
- Period
- 2023-08-01 → 2024-07-31
Description
ABSTRACT Chronic alcohol consumption is a significant issue worldwide which can lead to addiction and damage throughout the body. The first step in alcohol metabolism is its conversion into acetaldehyde, which is a highly reactive and toxic molecule. The formation of acetaldehyde adducts with protein and DNA is a primary mechanism of ethanol toxicity. Acetaldehyde adducts are a direct biomarker for alcohol abuse. We intend to develop a facile and rapid enzyme-based assay for measuring acetaldehyde-protein adducts to assess alcohol use and alcohol-related health consequences.